 AN experimental drug for Covid-19 has put the spotlight on barriers to treatment for millions of people on the basis of marketing decisions by pharmaceutical companies. Malaysia has been excluded from a list of 127 nations that can have access to a generic form of Remdesivir, which US drug maker Gilead Sciences is allowing five manufacturers of generics to produce and market to the countries on the list. 